THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Biomanufacturing demands precision at every turn—whether safeguarding sensitive biologics like monoclonal antibodies and live cells or ensuring accurate flow rates and overall system efficiency. Bioprocessing pumps are at the heart of this operation, entrusted with delivering fluids steadily and consistently. Yet, traditional pumps—hampered by pulsation, shear stress, and inherent inefficiencies—have historically imperiled product integrity and raised operational costs. Alphinity is changing that equation. Evolving from ARTeSYN BioSolutions, a trailblazer in valve technology, Alphinity was founded with a singular mission: to transcend the limitations of conventional peristaltic, diaphragm, and centrifugal pumps. The company’s flagship innovation, PIXER® , is a singleuse component that seamlessly merges pumping and mixing functions while adhering to Pharma 4.0 standards. “Innovation is our heartbeat at Alphinity. With PIXER® , we’re not just refining fluid management—we’re pioneering a new era in bioprocessing where precision, efficiency, and patient wellbeing converge to deliver transformative, life-saving therapies,” says Craig Vincze, Vice President & Co-Founder. PIXER®: A Breakthrough in Fluid Management Pulsation at the pump outlet is a significant challenge for bioprocessing, disrupting electronic flow sensors and causing flow rate and pressure fluctuations. PIXER® eliminates these issues, ensuring smooth, precise fluid movement while optimizing efficiency. Designed for high-value biologics, it minimizes shear stress, operates at high pressures, and efficiently handles viscous fluids. PIXER® ’s top inlet placement is a key mechanical innovation that allows direct positioning beneath a fluid reservoir, such as a bioreactor or retentate tank, in a tangential flow filtration (TFF) system. Unlike conventional pumps with side-positioned inlets, this vertical orientation leverages gravity for continuous fluid feed, enhancing suction efficiency and preventing air entrapment and cavitation—common issues in horizontal pump designs. This gravity-assisted design also reduces footprint and prevents tubing collapse under suction pressure, which is particularly beneficial for handling high-viscosity fluids or high flow rates.
Professor Sir Peter Donnelly, Founder & CEO, Dave Thornton, President
At a time when predictive and precision medicine has moved from aspiration to critical importance, Genomics—a biotechnology research company—is driving the shift to make these advancements the new standard in healthcare and life sciences. Founded in Oxford and rapidly expanding to other key hubs like Cambridge, London and even overseas in the U.S., Genomics has become a frontrunner in the global quest to unlock the potential of genomics to help people live healthier, longer lives. Its advanced statistical analysis platform harnesses powerful algorithms and a vast genome-phenome database, providing pharmaceutical companies with critical insights into genetic variation and its connection to human diseases. Augmented with cutting-edge AI and ML tools, this platform delivers quick, deep analyses that identify diseases’ causes and consequences. By maintaining one of the world’s most comprehensive genotypephenotype databases, Genomics supports rapid and effective decision-making across all therapeutic areas, fundamentally enhancing drug R&D and the development of targeted, personalised treatments. Such robust infrastructure empowers it to drive significant medical breakthroughs and meet unmet medical needs effectively.
Steve Madsen, CEO
Serialization in the pharmaceutical industry isn’t just about regulatory compliance—it’s about ensuring patient safety and supply chain integrity. However, achieving compliance can be challenging, as companies often struggle with fragmented systems, data inconsistencies, and the complexity of global regulatory requirements. Many businesses rely on separate serialization solutions that do not integrate with their ERP systems, leading to inefficiencies and gaps in tracking. This is where RxERP changes the game. As the sole provider of a serialized ERP system, RxERP is a trusted partner for pharmaceutical companies seeking an industry-specific, cloud-hosted platform to automate drug serialization and tracking across the supply chain. The platform’s distinctive framework embeds serialization directly into the core ERP system, streamlining compliance, improving visibility, and enabling accurate, real-time data exchange across the supply chain. “Our platform helps ensure adherence to regulations like the Drug Supply Chain Security Act (DSCSA), minimizing risks and maintaining the highest standards for manufacturers, wholesale distributors, and 3PL providers,” says Steve Madsen, CEO of RxERP. This platform additionally features licensure verification, inventory and warehouse management, CRM, and a white-label e-Commerce solution equipped with PCI-compliant checkout capabilities. By consolidating these capabilities into a single system, RxERP eliminates inefficiencies caused by disconnected solutions, allowing pharmaceutical companies to manage end-to-end supply chain operations seamlessly. For pharmaceutical companies, compliance challenges range from product serialization and traceability to maintaining data integrity and regulatory reporting. RxERP addresses these concerns by ensuring that each drug package remains distinctly identifiable throughout its journey, preventing counterfeit products from infiltrating the market. The system safeguards data accuracy regarding product movements, expiration dates, and inventory levels to prevent the distribution of expired medications. It also streamlines regulatory reporting by automatically generating and submitting essential documentation to authorities like the FDA, simplifying an otherwise complex and time consuming process.
Pharma Safety & Compliance
Tim Stow, Global Head of Ethics & Compliance, Galderma
Pharma Consulting
Melissa Lore, Chief Compliance Officer, FFF Enterprises, Inc
Pharma Manufacturing
Armand Matejunas, Sr. Director, Clinical Data Operations, Pacira BioSciences, Inc
Drug Discovery Enabling
Hua Gong, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab (US) LLC
Pharma Consulting
Jennifer Perrin, Director, MMS Holdings Inc
Bioprocessing pump manufacturing is crucial in the biopharmaceutical, biotechnology, and industrial sectors.
Pharmaceutical compliance solutions have become a cornerstone of the modern healthcare industry, ensuring companies adhere to ever-evolving regulations, avoid legal risks, and maintain ethical standards.
Smarter, Faster, and More Precise
Regulatory complexity has long been a roadblock, but leading compliance providers are flipping the script. AI-powered platforms do not just react to risks but predict and prevent them. Companies that master regulatory agility will avoid penalties, gain faster approvals, and gain a competitive edge over those still tangled in red tape.
Drug discovery is evolving beyond trial and error. AI and machine learning are transforming molecular screening, dramatically reducing research timelines. Quantum computing simulations help scientists predict drug interactions before the first lab test. Precision medicine is advancing with AI-driven biomarker identification, shifting personalized treatment from theory to practice.
On the manufacturing front, bioprocessing is undergoing a quiet revolution. Advanced pump systems may not make headlines, but they are the backbone of pharmaceutical production. Fluid management must be flawless as gene therapies, monoclonal antibodies, and mRNA vaccines become mainstream. Smart pumps with IoT connectivity adjust in real-time, predict maintenance needs, and integrate seamlessly into automated workflows.
With a projected 6.15 percent CAGR, the pharmaceutical market will reach $3.03 trillion by 2034, underscoring the industry’s rapid transformation through AI, automation, and next-generation manufacturing.
This Pharma Tech Outlook Magazine brings thought leadership articles from Hua Gong, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab (US) LLC on how spatial omics technologies revolutionize oncology drug discovery by enhancing biomarker identification, drug target validation, and precision medicine strategies. Another featured article by Jennifer Perrin, Associate Director of Quality & Compliance at MMS Holdings Inc., explores the strategic benefits of outsourcing pharmaceutical quality functions, emphasizing cost efficiency, regulatory compliance, and the importance of expert selection.
This edition features the Top Pharma Compliance Solutions Provider 2025, Top Drug Discovery and Development Solutions Provider 2025 and Bioprocessing Pump Manufacturing Company of the Year 2025. We hope you find the right partner to meet your organization’s needs.
